Screening for type 2 diabetes

Podcast & Infographic

Screening for type 2 diabetes

E-learning Modules

Launch: 15 July 2024


The delay in diagnosis of pre-diabetes and diabetes is a world-wide problem. In order to help address this delay, the joint ADA and EASD 2022 guidelines, recommend screening for type 2 diabetes in adults from 35 years of age [ElSayed, 2022; Davies, 2022]. If the results are recorded as normal, it is recommended to test at a minimum of 3-year intervals. For those with risk factors i.e. overweight/obese, high-risk race/ethnicity, physically inactive, hypertension, the guidelines suggest screening should begin earlier than 35 years and occur more frequently e.g. National Clinical Guidelines in Pakistan recommend to start at 30 years [Martins, 2023].

In children and adolescents who are overweight or obese, or who have risk factors for diabetes, testing should be considered after the onset of puberty [ElSayed, 2022].

The aim of screening asymptomatic adults for pre-diabetes and type 2 diabetes is to facilitate earlier detection, diagnosis, and treatment, with the ultimate goal of improving health outcomes by preventing the development of secondary complications, particularly blindness and kidney failure [Davidson, 2021].

However, there is some uncertainty about the effects of screening for type 2 diabetes on all‐cause and diabetes‐related mortality [Jonas, 2021; Peer, 2020]. Research is needed to produce reliable and accurate biomarkers for diabetes and pre-diabetes [Ortez-Martinez, 2022] that can be used globally for community screening as well as education and community out-reach projects to encourage individuals to attend. 

Learning Objectives

After listening to this podcast, participants will be able to:

Target Audience

Clinicians involved in endocrinology, particularly diabetes, pre-diabetes; fertility and pregnancy management, obesity management and general practice; some content of interest to midwives and nurses involved in pre-natal and post-natal care; some content of interest to vascular specialists and podiatrists.


English with voice-over into Spanish and Chinese


Antonio Ceriello

Antonio Ceriello

IRCCS MultiMedica
Milan, Italy

Sign up for the module

Final Programme

Download Final Programme

· Antonio Ceriello ·

Antonio Ceriello is currently an award-winning research consultant at Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy. He has worked internationally both clinically and in research.
His research interests are centred around cardiovascular disease and diabetes. He was a consultant with the National Institute of Health (NIH), in the US from 2003–2005, and a member of the writing committee for the American Heart Association Guidelines on Acute Hyperglycemia and Acute Coronary Syndromes. He has been instrumental in both the development (2008) and the update (2011) of the International Diabetes Federation (IDF) Committee Guidelines for Management of Post-meal Glucose. Currently, he is the Chairman of the Diabetes and Cardiovascular Diseases Study Group of the European Association for the Study of Diabetes (EASD). Professor Ceriello has been involved with numerous guidelines including the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (2012), European Society of Cardiology (ESC) Guidelines on Diabetes, Pre-diabetes, and Cardiovascular Diseases developed in collaboration with the EASD (2013 and 2019), and the Continuous Glucose Monitoring Metrics for Clinical Trials International Consensus developed by the ADA, ADCES, EASD, ISPAD, JDS, JDRF and endorsed by the FDA and EMA (2022). He has been appointed by IDF as Co-Chairman for the development of the 2023 Guidelines for the Management of Type 2 Diabetes in Different Settings and as Chairman for the 2024 IDF Global Meeting. He is also currently the IDF representative for global action for developing a research and action roadmap for fatty liver disease, as well as developing the IDF-ISN policy brief on diabetic nephropathy (in co-operation with WHO) and the obesity cinical practice recommendation and education project (in cooperation with WOF).
Professor Ceriello has published over 500 original papers and several book chapters. His current h-index is 119 (Google Scholar). He served as Associate Editor of Diabetes Care (2003–2011) and Diabetic Medicine (2005–2016). Currently he is Editor-in-Chief of Diabetes Research and Clinical Practice, the official IDF journal (current IF 8.18) and serves on the editorial board of Cardiovascular Diabetology.

· Martin O. Savage ·

Martin Savage is Emeritus Professor of Paediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary, University of London. He was head of the Paediatric Endocrine Unit at Barts and the London School of Medicine from 1982 to 2007. He has interests in growth disorders, specifically those with abnormalities in the GH-IGF-1 axis and in phenotype-genotype relationships of GH-IGF-1 axis defects, notably GH resistance. He published the first human case of an IGF-1 gene defect in the New England Journal of Medicine in 1996.  His other interests are Cushing’s syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. He has lectured in 61 countries and has published 472 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology and in 2018 he received a Visionary Award from the American Human Growth Foundation. In 2022, he received a Research Excellence Award from the Dr Sulaiman Al Habib Medical Journal in Riyadh, and the British Society of Paediatric Endocrinology & Diabetes James M. Tanner Lifetime Achievement Award. He continues to lecture nationally and internationally.